Literature DB >> 16567826

Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy.

Tadashi Konoshita1, Shigeyuki Wakahara, Shinichi Mizuno, Makoto Motomura, Chikako Aoyama, Yasukazu Makino, Yasuyuki Kawai, Norihiro Kato, Ichiro Koni, Isamu Miyamori, Hiroshi Mabuchi.   

Abstract

OBJECTIVE: Recent studies have proved that blockade of the renin-angiotensin system (RAS) retards the progression of diabetic nephropathy, whereas hyporeninemia is known as a typical state in diabetic subjects. The purpose of this study is to determine whether expression levels of RAS differ between nondiabetic and diabetic renal tissues with accurate quantitative method. RESEARCH DESIGN AND METHODS: Subjects were 66 nondiabetic and 8 diabetic patients with biopsy-proven renal diseases. The eight diabetic subjects suffered from type 2 diabetes with overt proteinuria. Renal histology revealed typical diffuse or nodular lesions with linear IgG deposit on immunofluorescent staining and thickened basement membrane on electronic microscopy. Total RNA from a small part of the renal cortical biopsy specimens was reverse-transcribed, and the resultant cDNA was amplified for new major components of RAS (i.e., renin, renin receptor, angiotensinogen, ACE, ACE2, angiotensin II type 1 receptor, and angiotensin II type 2 receptor) and measured.
RESULTS: Among these components, a significant upregulation was observed in the ACE gene in diabetic renal tissue.
CONCLUSIONS: The results suggest that renal tissue RAS might be activated in the respect that ACE gene expression is upregulated in spite of a tendency to low renin expression in type 2 diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16567826     DOI: 10.2337/diacare.29.04.06.dc05-1873

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  31 in total

1.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

Review 2.  ACE and ACE2 in kidney disease.

Authors:  Sonoo Mizuiri; Yasushi Ohashi
Journal:  World J Nephrol       Date:  2015-02-06

3.  Activation of skin renin-angiotensin system in diabetic rats.

Authors:  Shao Yun Hao; Meng Ren; Chuan Yang; Diao Zhu Lin; Li Hong Chen; Ping Zhu; Hua Cheng; Li Yan
Journal:  Endocrine       Date:  2011-04-12       Impact factor: 3.633

Review 4.  The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function.

Authors:  Carlos M Ferrario; Jasmina Varagic
Journal:  Am J Physiol Renal Physiol       Date:  2010-04-07

Review 5.  Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management.

Authors:  Peter N Van Buren; Robert Toto
Journal:  Adv Chronic Kidney Dis       Date:  2011-01       Impact factor: 3.620

6.  Amelioration of Diabetic Nephropathy Using a Retinoic Acid Receptor β2 Agonist.

Authors:  Steven E Trasino; Xiao-Han Tang; Maria M Shevchuk; Mary E Choi; Lorraine J Gudas
Journal:  J Pharmacol Exp Ther       Date:  2018-07-27       Impact factor: 4.030

7.  Calcitriol regulates angiotensin-converting enzyme and angiotensin converting-enzyme 2 in diabetic kidney disease.

Authors:  Mei Lin; Ping Gao; Tianya Zhao; Lei He; Mengshi Li; Yaoyao Li; Hua Shui; Xiaoyan Wu
Journal:  Mol Biol Rep       Date:  2016-03-12       Impact factor: 2.316

8.  Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy.

Authors:  G Wang; F M-M Lai; K-B Lai; K-M Chow; C-H B Kwan; K-T P Li; C-C Szeto
Journal:  Diabetologia       Date:  2008-04-04       Impact factor: 10.122

Review 9.  The sweeter side of ACE2: physiological evidence for a role in diabetes.

Authors:  Sharell M Bindom; Eric Lazartigues
Journal:  Mol Cell Endocrinol       Date:  2008-10-01       Impact factor: 4.102

10.  Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition.

Authors:  Elena Velkoska; Rachael G Dean; Luke Burchill; Vicki Levidiotis; Louise M Burrell
Journal:  Clin Sci (Lond)       Date:  2010-02       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.